T Jake Liang1, Timothy M Block2, Brian J McMahon3, Marc G Ghany1, Stephan Urban4, Ju-Tao Guo2, Stephen Locarnini5, Fabien Zoulim6, Kyong-Mi Chang7, Anna S Lok8. 1. Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD. 2. Baruch S. Blumberg Institute, Doylestown, PA. 3. National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Anchorage, AK. 4. Department of Infectious Diseases, Molecular Virology and German Center for Infection Diseases, University Hospital Heidelberg, Heidelberg, Germany. 5. Hepatology Department, Lyon University and Cancer Research Center of Lyon, INSERM U1052, Lyon, France. 6. Victorian Infectious Diseases Reference Laboratory, Doherty Institute, Melbourne, VIC, Australia. 7. Department of Medicine, Philadelphia Veterans Affairs Medical Center and the University of Pennsylvania Perelman School of Medicine, Philadelphia, PA. 8. Division of Gastroenterology and Hepatology, University of Michigan, Ann Arbor, MI.
Abstract
UNLABELLED: Hepatitis B virus (HBV) is a significant global pathogen, infecting more than 240 million people worldwide. While treatment for HBV has improved, HBV patients often require lifelong therapies and cure is still a challenging goal. Recent advances in technologies and pharmaceutical sciences have heralded a new horizon of innovative therapeutic approaches that are bringing us closer to the possibility of a functional cure of chronic HBV infection. In this article, we review the current state of science in HBV therapy and highlight new and exciting therapeutic strategies spurred by recent scientific advances. Some of these therapies have already entered into clinical phase, and we will likely see more of them moving along the development pipeline. CONCLUSION: With growing interest in developing and efforts to develop more effective therapies for HBV, the challenging goal of a cure may be well within reach in the near future.
UNLABELLED: Hepatitis B virus (HBV) is a significant global pathogen, infecting more than 240 million people worldwide. While treatment for HBV has improved, HBVpatients often require lifelong therapies and cure is still a challenging goal. Recent advances in technologies and pharmaceutical sciences have heralded a new horizon of innovative therapeutic approaches that are bringing us closer to the possibility of a functional cure of chronic HBV infection. In this article, we review the current state of science in HBV therapy and highlight new and exciting therapeutic strategies spurred by recent scientific advances. Some of these therapies have already entered into clinical phase, and we will likely see more of them moving along the development pipeline. CONCLUSION: With growing interest in developing and efforts to develop more effective therapies for HBV, the challenging goal of a cure may be well within reach in the near future.
Authors: H Fontaine; S Kahi; C Chazallon; M Bourgine; A Varaut; C Buffet; O Godon; J F Meritet; Y Saïdi; M L Michel; D Scott-Algara; J P Aboulker; S Pol Journal: Gut Date: 2014-02-20 Impact factor: 23.059
Authors: Frédéric M Vaz; Coen C Paulusma; Hidde Huidekoper; Minke de Ru; Cynthia Lim; Janet Koster; Kam Ho-Mok; Albert H Bootsma; Albert K Groen; Frank G Schaap; Ronald P J Oude Elferink; Hans R Waterham; Ronald J A Wanders Journal: Hepatology Date: 2014-08-25 Impact factor: 17.425
Authors: Nagraj Mani; Andrew G Cole; Janet R Phelps; Andrzej Ardzinski; Kyle D Cobarrubias; Andrea Cuconati; Bruce D Dorsey; Ellen Evangelista; Kristi Fan; Fang Guo; Haitao Guo; Ju-Tao Guo; Troy O Harasym; Salam Kadhim; Steven G Kultgen; Amy C H Lee; Alice H L Li; Quanxin Long; Sara A Majeski; Richeng Mao; Kevin D McClintock; Stephen P Reid; Rene Rijnbrand; Nicholas M Snead; Holly M Micolochick Steuer; Kim Stever; Sunny Tang; Xiaohe Wang; Qiong Zhao; Michael J Sofia Journal: Antimicrob Agents Chemother Date: 2018-05-25 Impact factor: 5.191